NA Thyroid Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The North America thyroid cancer diagnostics market is projected to register a substantial CAGR of 6.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Thyroid Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, Others), Cancer Type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group ( 30-65, 65 and above, 21-29, Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the North America thyroid cancer diagnostics market are:

Rising incidence and prevalence of thyroid nodules & cancer

Rising thyroid cancer diagnostic tests rise in product approvals

Rising awareness towards thyroid cancer

Market Players:

Some major companies which are dealing in the North America thyroid cancer diagnostics market are listed below:

Canon Inc.

FUJIFILM Holdings Corporation

F. Hoffmann-La Roche Ltd

Quest Diagnostics Incorporated

Illumina

Koninklijke Philips N.V.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

Abbott

General Electric Company

QIAGEN

DIASORIN S.P.A.

Merck KGaA

Hologic

Myriad Genetics Inc.

BIOMERIEUX

FONAR Corp.

Time Medical Holding.

MinFound Medical Systems Co., Ltd

1 INTRODUCTION 46

1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48

2 MARKET SEGMENTATION 51

2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET TESTING TYPE COVERAGE GRID 61
2.11 VENDOR SHARE ANALYSIS 62
2.12 SECONDARY SOURCES 63
2.13 ASSUMPTIONS 63

3 EXECUTIVE SUMMARY 64

4 PREMIUM INSIGHTS 67

4.1 PESTEL ANALYSIS 68
4.2 PORTER'S FIVE FORCES 69
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 70

5 EPIDEMIOLOGY 71

6 REGULATORY FRAMEWORK OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET 72

6.1 REGULATORY SCENARIO IN THE U.S. 72
6.2 REGULATORY SCENARIO IN AUSTRALIA 73
6.3 REGULATORY SCENARIO IN JAPAN 73
6.4 REGULATORY SCENARIO IN CHINA 73

7 MARKET OVERVIEW 74

7.1 DRIVERS 76
- 7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER 76
- 7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS 76
- 7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 77
- 7.1.4 RISING AWARENESS TOWARDS THYROID CANCER 77
7.2 RESTRAINTS 78
- 7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE 78
- 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 79
7.3 OPPORTUNITIES 79
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 79
- 7.3.2 RISING OBESE POPULATION 80
7.4 CHALLENGES 80
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 80
- 7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 81

8 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 82

8.1 OVERVIEW 83
8.2 INSTRUMENTS 86
- 8.2.1 PATHOLOGY BASED INSTRUMENTS 87
  - 8.2.1.1 PCR INSTRUMENTS 87
  - 8.2.1.2 SLIDE STAINING SYSTEMS 87
  - 8.2.1.3 TISSUE PROCESSING SYSTEMS 87
  - 8.2.1.4 CELL PROCESSORS 88
  - 8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 88
- 8.2.2 IMAGING INSTRUMENTS 88
  - 8.2.2.1 ULTRASOUND SYSTEMS 88
  - 8.2.2.2 CT SYSTEMS 88
  - 8.2.2.3 MRI SYSTEMS 88
  - 8.2.2.4 OTHERS 88
- 8.2.3 BIOPSY INSTRUMENTS 89
  - 8.2.3.1 NEEDLE BIOPSY 89
  - 8.2.3.2 ENDOSCOPIC BIOPSY 89
  - 8.2.3.3 CORE BIOPSY 89
  - 8.2.3.4 OTHERS 89
- 8.2.4 OTHERS 89
8.3 CONSUMABLES & ACCESSORIES 90
- 8.3.1 KITS 91
  - 8.3.1.1 PCR KITS 91
  - 8.3.1.2 DNA POLYMERASE KITS 91
  - 8.3.1.3 NUCLEIC ACID ISOLATION KITS 91
  - 8.3.1.4 OTHERS 91
- 8.3.2 REAGENTS 92
  - 8.3.2.1 ASSAYS 92
  - 8.3.2.2 BUFFERS 92
  - 8.3.2.3 PRIMERS 92
  - 8.3.2.4 OTHERS 92
- 8.3.3 PROBES 92
- 8.3.4 OTHER CONSUMABLES 92

9 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 93

9.1 OVERVIEW 94
9.2 IMAGING TEST 97
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 98
- 9.2.2 MRI 98
- 9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 98
- 9.2.4 OTHERS 98
9.3 BLOOD TEST 99
- 9.3.1 BLOOD CHEMISTRY TESTS 100
- 9.3.2 COMPLETE BLOOD COUNT (CBC) 100
- 9.3.3 OTHERS 100
9.4 BIOPSY 100
- 9.4.1 NEEDLE BIOPSY 101
- 9.4.2 BRONCHOSCOPY BIOPSY 101
- 9.4.3 CORE BIOPSY 101
- 9.4.4 OTHERS 101
9.5 OTHERS 102

10 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 103

10.1 OVERVIEW 104
10.2 PAPILLARY CARCINOMA 107
10.3 FOLLICULAR CARCINOMA 108
10.4 OTHERS 109

11 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 110

11.1 OVERVIEW 111
11.2 STAGE I 114
11.3 STAGE II 115
11.4 STAGE III 116
11.5 STAGE IV 117

12 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 118

12.1 OVERVIEW 119
12.2 30-65 122
12.3 65 AND ABOVE 123
12.4 21-29 124
12.5 BELOW 21 125

13 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER 126

13.1 OVERVIEW 127
13.2 HOSPITALS 130
13.3 ASSOCIATED LABS 131
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131
13.5 DIAGNOSTIC IMAGING CENTERS 132
13.6 CANCER RESEARCH INSTITUTES 133
13.7 OTHERS 134

14 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135

14.1 OVERVIEW 136
14.2 DIRECT TENDER 139
14.3 RETAIL SALES 140

15 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY REGION 141

15.1 NORTH AMERICA 142
- 15.1.1 U.S. 152
- 15.1.2 CANADA 157
- 15.1.3 MEXICO 162

16 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 167

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 167

17 SWOT ANALYSIS 168

18 COMPANY PROFILE 169

18.1 CANON INC. 169
- 18.1.1 COMPANY SNAPSHOT 169
- 18.1.2 COMPANY SHARE ANALYSIS 169
- 18.1.3 PRODUCT PORTFOLIO 170
- 18.1.4 RECENT DEVELOPMENTS 170
18.2 FUJIFILM CORPORATION 171
- 18.2.1 COMPANY SNAPSHOT 171
- 18.2.2 REVENUE ANALYSIS 171
- 18.2.3 COMPANY SHARE ANALYSIS 172
- 18.2.4 PRODUCT PORTFOLIO 172
- 18.2.5 RECENT DEVELOPMENT 172
18.3 F. HOFFMANN-LA ROCHE LTD 173
- 18.3.1 COMPANY SNAPSHOT 173
- 18.3.2 REVENUE ANALYSIS 173
- 18.3.3 COMPANY SHARE ANALYSIS 174
- 18.3.4 PRODUCT PORTFOLIO 174
- 18.3.5 RECENT DEVELOPMENT 174
18.4 QUEST DIAGNOSTICS INCORPORATED 175
- 18.4.1 COMPANY SNAPSHOT 175
- 18.4.2 REVENUE ANALYSIS 175
- 18.4.3 COMPANY SHARE ANALYSIS 176
- 18.4.4 PRODUCT PORTFOLIO 176
- 18.4.5 RECENT DEVELOPMENTS 176
18.5 ILLUMINA, INC. 178
- 18.5.1 COMPANY SNAPSHOT 178
- 18.5.2 REVENUE ANALYSIS 178
- 18.5.3 COMPANY SHARE ANALYSIS 179
- 18.5.4 PRODUCT PORTFOLIO 179
- 18.5.5 RECENT DEVELOPMENT 179
18.6 ABBOTT 180
- 18.6.1 COMPANY SNAPSHOT 180
- 18.6.2 REVENUE ANALYSIS 180
- 18.6.3 PRODUCT PORTFOLIO 181
- 18.6.4 RECENT DEVELOPMENT 181
18.7 BD 182
- 18.7.1 COMPANY SNAPSHOT 182
- 18.7.2 REVENUE ANALYSIS 182
- 18.7.3 PRODUCT PORTFOLIO 183
- 18.7.4 RECENT DEVELOPMENT 183
18.8 BEIJING O&D BIOTECH CO., LTD. 184
- 18.8.1 COMPANY SNAPSHOT 184
- 18.8.2 PRODUCT PORTFOLIO 184
- 18.8.3 RECENT DEVELOPMENTS 184
18.9 BIOMERIEUX SA 185
- 18.9.1 COMPANY SNAPSHOT 185
- 18.9.2 REVENUE ANALYSIS 185
- 18.9.3 PRODUCT PORTFOLIO 186
- 18.9.4 RECENT DEVELOPMENTS 186
18.10 DIASORIN S.P.A. 187
- 18.10.1 COMPANY SNAPSHOT 187
- 18.10.2 REVENUE ANALYSIS 187
- 18.10.3 PRODUCT PORTFOLIO 188
- 18.10.4 RECENT DEVELOPMENT 188
18.11 FONAR CORP. 189
- 18.11.1 COMPANY SNAPSHOT 189
- 18.11.2 REVENUE ANALYSIS 189
- 18.11.3 PRODUCT PORTFOLIO 190
- 18.11.4 RECENT DEVELOPMENTS 190
18.12 GENERAL ELECTRIC 191
- 18.12.1 COMPANY SNAPSHOT 191
- 18.12.2 REVENUE ANALYSIS 191
- 18.12.3 PRODUCT PORTFOLIO 192
- 18.12.4 RECENT DEVELOPMENTS 192
18.13 HOLOGIC INC. 193
- 18.13.1 COMPANY SNAPSHOT 193
- 18.13.2 REVENUE ANALYSIS 193
- 18.13.3 PRODUCT PORTFOLIO 194
- 18.13.4 RECENT DEVELOPMENT 194
18.14 KONINKLIJKE PHILIPS N.V. 195
- 18.14.1 COMPANY SNAPSHOT 195
- 18.14.2 REVENUE ANALYSIS 195
- 18.14.3 PRODUCT PORTFOLIO 196
- 18.14.4 RECENT DEVELOPMENT 196
18.15 MERCK KGAA. 197
- 18.15.1 COMPANY SNAPSHOT 197
- 18.15.2 REVENUE ANALYSIS 197
- 18.15.3 PRODUCT PORTFOLIO 198
- 18.15.4 RECENT DEVELOPMENT 198
18.16 MEDONICA CO. LTD 199
- 18.16.1 COMPANY SNAPSHOT 199
- 18.16.2 PRODUCT PORTFOLIO 199
- 18.16.3 RECENT DEVELOPMENT 199
18.17 MINFOUND MEDICAL SYSTEMS CO. LTD 200
- 18.17.1 COMPANY SNAPSHOT 200
- 18.17.2 PRODUCT PORTFOLIO 200
- 18.17.3 RECENT DEVELOPMENTS 201
18.18 MYRIAD GENETICS, INC. 202
- 18.18.1 COMPANY SNAPSHOT 202
- 18.18.2 REVENUE ANALYSIS 202
- 18.18.3 PRODUCT PORTFOLIO 203
- 18.18.4 RECENT DEVELOPMENTS 203
18.19 PLEXBIO. 204
- 18.19.1 COMPANY SNAPSHOT 204
- 18.19.2 PRODUCT PORTFOLIO 204
- 18.19.3 RECENT DEVELOPMENTS 204
18.20 QIAGEN 205
- 18.20.1 COMPANY SNAPSHOT 205
- 18.20.2 REVENUE ANALYSIS 205
- 18.20.3 PRODUCT PORTFOLIO 206
- 18.20.4 RECENT DEVELOPMENT 206
18.21 STERNMED GMBH 207
- 18.21.1 COMPANY SNAPSHOT 207
- 18.21.2 PRODUCT PORTFOLIO 207
- 18.21.3 RECENT DEVELOPMENTS 207
18.22 SIEMENS HEALTHCARE GMBH 208
- 18.22.1 COMPANY SNAPSHOT 208
- 18.22.2 REVENUE ANALYSIS 208
- 18.22.3 PRODUCT PORTFOLIO 209
- 18.22.4 RECENT DEVELOPMENT 209
18.23 TIME MEDICAL HOLDING. 210
- 18.23.1 COMPANY SNAPSHOT 210
- 18.23.2 PRODUCT PORTFOLIO 210
- 18.23.3 RECENT DEVELOPMENT 210
18.24 THERMO FISHER SCIENTIFIC INC. 211
- 18.24.1 COMPANY SNAPSHOT 211
- 18.24.2 REVENUE ANALYSIS 211
- 18.24.3 PRODUCT PORTFOLIO 212
- 18.24.4 RECENT DEVELOPMENT 212

19 QUESTIONNAIRE 213

LIST OF TABLES

TABLE 1 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 59
TABLE 2 NORTH AMERICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 3 NORTH AMERICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 61
TABLE 4 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 61
TABLE 5 NORTH AMERICA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 62
TABLE 6 NORTH AMERICA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 63
TABLE 7 NORTH AMERICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 8 NORTH AMERICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65
TABLE 9 NORTH AMERICA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 65
TABLE 10 NORTH AMERICA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 66
TABLE 11 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 70
TABLE 12 NORTH AMERICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 13 NORTH AMERICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
TABLE 14 NORTH AMERICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 15 NORTH AMERICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 74
TABLE 16 NORTH AMERICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 17 NORTH AMERICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 75
TABLE 18 NORTH AMERICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 19 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 80
TABLE 20 NORTH AMERICA PAPILLARY CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 21 NORTH AMERICA FOLLICULAR CARCINOMA IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 22 NORTH AMERICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 23 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 87
TABLE 24 NORTH AMERICA STAGE I IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 25 NORTH AMERICA STAGE II IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 26 NORTH AMERICA STAGE III IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 27 NORTH AMERICA STAGE IV IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 28 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 95
TABLE 29 NORTH AMERICA 30-65 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 30 NORTH AMERICA 65 AND ABOVE IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 31 NORTH AMERICA 21-29 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 32 NORTH AMERICA BELOW 21 IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 33 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 103
TABLE 34 NORTH AMERICA HOSPITALS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 35 NORTH AMERICA ASSOCIATED LABS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 36 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 37 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 38 NORTH AMERICA CANCER RESEARCH INSTITUTES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 39 NORTH AMERICA OTHERS IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 40 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 112
TABLE 41 NORTH AMERICA DIRECT TENDER IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 42 NORTH AMERICA RETAIL SALES IN THYROID CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 43 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 121
TABLE 44 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
TABLE 45 NORTH AMERICA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
TABLE 46 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 121
TABLE 47 NORTH AMERICA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 48 NORTH AMERICA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 49 NORTH AMERICA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 50 NORTH AMERICA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
TABLE 51 NORTH AMERICA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
TABLE 52 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
TABLE 53 NORTH AMERICA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
TABLE 54 NORTH AMERICA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
TABLE 55 NORTH AMERICA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 124
TABLE 56 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 124
TABLE 57 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 125
TABLE 58 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 125
TABLE 59 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 125
TABLE 60 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 125
TABLE 61 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 62 U.S. INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 63 U.S. PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 64 U.S. IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 65 U.S. BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 66 U.S. CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 67 U.S. KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 68 U.S. REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 69 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
TABLE 70 U.S. IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
TABLE 71 U.S. BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 72 U.S. BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 73 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 129
TABLE 74 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 129
TABLE 75 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 130
TABLE 76 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 77 U.S. THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 130
TABLE 78 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 131
TABLE 79 CANADA INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 131
TABLE 80 CANADA PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 131
TABLE 81 CANADA IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 82 CANADA BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 83 CANADA CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 84 CANADA KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 85 CANADA REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 133
TABLE 86 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
TABLE 87 CANADA IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
TABLE 88 CANADA BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
TABLE 89 CANADA BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
TABLE 90 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 134
TABLE 91 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 134
TABLE 92 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 135
TABLE 93 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 94 CANADA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 135
TABLE 95 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 96 MEXICO INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 97 MEXICO PATHOLOGY-BASED INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136
TABLE 98 MEXICO IMAGING INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 137
TABLE 99 MEXICO BIOPSY INSTRUMENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 137
TABLE 100 MEXICO CONSUMABLES & ACCESSORIES IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 137
TABLE 101 MEXICO KITS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
TABLE 102 MEXICO REAGENTS IN THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
TABLE 103 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
TABLE 104 MEXICO IMAGING TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
TABLE 105 MEXICO BIOPSY IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
TABLE 106 MEXICO BLOOD TEST IN THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
TABLE 107 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 139
TABLE 108 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY STAGES, 2021-2030 (USD MILLION) 139
TABLE 109 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 140
TABLE 110 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 140
TABLE 111 MEXICO THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 140

LIST OF FIGURES

FIGURE 1 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION 23
FIGURE 2 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 26
FIGURE 3 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 27
FIGURE 4 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 30
FIGURE 7 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 31
FIGURE 8 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID 33
FIGURE 9 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 34
FIGURE 10 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: SEGMENTATION 38
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT THYROID CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD 39
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET IN 2023 & 2030 39
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET 47
FIGURE 14 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 55
FIGURE 15 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 56
FIGURE 16 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 56
FIGURE 17 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 57
FIGURE 18 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 66
FIGURE 19 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 67
FIGURE 20 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 67
FIGURE 21 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 68
FIGURE 22 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 76
FIGURE 23 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 77
FIGURE 24 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 77
FIGURE 25 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 78
FIGURE 26 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2022 83
FIGURE 27 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, 2023-2030 (USD MILLION) 84
FIGURE 28 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, CAGR (2023-2030) 84
FIGURE 29 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY STAGES, LIFELINE CURVE 85
FIGURE 30 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022 91
FIGURE 31 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 92
FIGURE 32 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 92
FIGURE 33 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 93
FIGURE 34 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2022 99
FIGURE 35 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 100
FIGURE 36 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 100
FIGURE 37 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 101
FIGURE 38 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 108
FIGURE 39 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 109
FIGURE 40 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 109
FIGURE 41 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 110
FIGURE 42 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 115
FIGURE 43 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 117
FIGURE 44 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 117
FIGURE 45 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 118
FIGURE 46 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 118
FIGURE 47 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 139